U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H27NO2
Molecular Weight 337.4553
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMINEPTINE

SMILES

OC(=O)CCCCCCNC1C2=CC=CC=C2CCC3=C1C=CC=C3

InChI

InChIKey=ONNOFKFOZAJDHT-UHFFFAOYSA-N
InChI=1S/C22H27NO2/c24-21(25)13-3-1-2-8-16-23-22-19-11-6-4-9-17(19)14-15-18-10-5-7-12-20(18)22/h4-7,9-12,22-23H,1-3,8,13-16H2,(H,24,25)

HIDE SMILES / InChI

Molecular Formula C22H27NO2
Molecular Weight 337.4553
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Amineptine is a selective inhibitor of dopamine reuptake. The drug was developed in France and was marketed for the treatment of depressive disorders under the name Survector among the others. Amineptine was withdrawn from the French market in 1999 because of abuse and drug dependence and because of its hepatic (cholestatic injuries) and cutaneous (acne) adverse effects.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Survector

Approved Use

Survector 100mg tablet is used in the treatment of depression.

Launch Date

1977
PubMed

PubMed

TitleDatePubMed
[Amineptine-induced cholestatic hepatitis. 5 cases (author's transl)].
1980 Dec 20
[The problem of side-effects: cardiotoxicity (author's transl)].
1981
[Hepatitis, cholestasis and amineptine (author's transl)].
1981 Dec 18-25
[Hepatitis caused by amineptine : a case with reintroduction of the drug].
1981 Nov
[Effects of thymo-analeptics and acceptability of amineptin compared to those of imipramine].
1982
[Extensive multicentric study of 1354 cases of depressed subjects treated with amineptin].
1982
[A study of three potential antidepressants (amineptin, mianserin and nomifensin) on the cardiovascular system and isolated intestine (author's transl)].
1982 Jun 10
[Amineptin-induced hepatitis: differential diagnosis of biliary microlithiasis].
1982 Nov
[Hepatitis due to amineptin. 4 cases].
1982 Nov
[Value of amineptin in the treatment of different depressive states. Apropos of 112 cases treated as part of a national multi-centric study].
1985 Jul-Aug
[Rosaceous drug eruption caused by amineptin (Survector)].
1988
[Iatrogenic acne caused by amineptin (Survector). Apropos of 8 cases].
1988
[Acneiform eruption induced by amineptin (Survector)].
1989
Genetic predisposition to drug hepatotoxicity: role in hepatitis caused by amineptine, a tricyclic antidepressant.
1989 Aug
[Amineptin dependence. Detection of patients at risk. Report of 8 cases].
1990 Sep-Oct
[Amineptin abuse. Analysis of 155 cases. An evaluation of the official cooperative survey of the Regional Centers of Pharmacovigilance].
1990 Sep-Oct
[Amineptin dependence and iatrogenic acne. Review of the literature apropos of a case].
1991 Dec
[Immediate acute hepatic cytolysis after the administration of a single amineptin tablet].
1992
The serotonin syndrome.
1992 Oct
[Acne induced by amineptin: adnexal toxiderma].
1996
Amineptine in the treatment of amphetamine withdrawal: a placebo-controlled, randomised, double-blind study.
1997 Sep
[A case of Parkinson syndrome secondary to combined amineptine and bromazepam abuse].
1998 Sep-Oct
Sleep-wake mechanisms and drug discovery: sleep EEG as a tool for the development of CNS-acting drugs.
2002 Dec
[Does addiction to antidepressants exist? About a case of one addiction to tianeptine].
2003 Sep-Oct
Role of presynaptic alpha2-adrenoceptors in antidepressant action: recent findings from microdialysis studies.
2004 Aug
Discriminating different classes of toxicants by transcript profiling.
2004 Aug
Sex-dependent modulation of treatment response.
2004 Mar
Fluoxetine dependence in a former amineptine abuser.
2004 Oct-Dec
Spectrophotometric determination of trazodone, amineptine and amitriptyline hydrochlorides through ion-pair formation with molybdenum and thiocyanate.
2006 Dec
Antidepressants for anorexia nervosa.
2006 Jan 25
Spectrophotometric determination of trazodone, amineptine and amitriptyline hydrochlorides through ion-pair formation using methyl orange and bromocresol green reagents.
2006 Sep
[A case of tianeptine abuse].
2006 Spring
Is it possible to be dependent to Tianeptine, an antidepressant? A case report.
2007 Apr 13
Utility of 7,7,8,8-tetracyanoquinodimethane charge transfer reagent for the spectrophotometric determination of trazodone, amineptine and amitriptyline hydrochlorides.
2007 Dec 31
Addressing the paradoxes of satisfaction with hospital care.
2008
Venlafaxine dependence in a patient with a history of alcohol and amineptine misuse.
2008 Sep
Improving pain management communication: how patients understand the terms "opioid" and "narcotic".
2008 Sep
Pharmacological and combined interventions for the acute depressive episode: focus on efficacy and tolerability.
2009
Update on the management of symptoms in schizophrenia: focus on amisulpride.
2009
Treatment for amphetamine withdrawal.
2009 Apr 15
Spectroscopic and electrochemical analysis of psychotropic drugs.
2009 Jan
[Acne induced by amineptine].
2009 Jan-Feb
Prevalence of antidepressants and biosimilars in elite sport.
2009 Jun
Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis.
2009 Jun
A new strategy for antidepressant prescription.
2010
Management of anorexia and bulimia nervosa: An evidence-based review.
2010 Apr
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.
2010 Dec
Amineptine treatment of persistent catatonic symptoms in schizophrenia: a controlled study.
2010 Dec
Research on antidepressants in India.
2010 Jan
Molecular biology research in neuropsychiatry: India's contribution.
2010 Jan
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Sources: www.ncbi.nlm.nih.gov/pubmed/21584062
Patients receive 200 mg of amineptine (survector) daily, in two divided doses at 8 A.M. and 12 noon for 6 weeks.
Route of Administration: Oral
In Vitro Use Guide
Rat neurones were treated with 300 nM-30uM of amineptine. Amineptine (1-30uM) decreased spontaneous firing and slightly hyperpolarized the membrane potential. At 300 nM-30uM amineptine increased the amplitude and duration of responses to exogenously applied dopamine.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:23:46 GMT 2023
Edited
by admin
on Fri Dec 15 16:23:46 GMT 2023
Record UNII
27T1I13L6G
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AMINEPTINE
INN   MI   WHO-DD  
INN  
Official Name English
7-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]heptanoic acid
Systematic Name English
AMINEPTINE [MI]
Common Name English
DEA NO. 1219
Common Name English
AMINEPTIN
Common Name English
Amineptine [WHO-DD]
Common Name English
amineptine [INN]
Common Name English
Classification Tree Code System Code
DEA NO. 1219
Created by admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
WHO-VATC QN06AA19
Created by admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
WHO-ATC N06AA19
Created by admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
NCI_THESAURUS C265
Created by admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID1048831
Created by admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
PRIMARY
SMS_ID
100000087225
Created by admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
PRIMARY
RXCUI
17698
Created by admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
PRIMARY RxNorm
INN
3998
Created by admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
PRIMARY
WIKIPEDIA
AMINEPTINE
Created by admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
PRIMARY
MESH
C011597
Created by admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
PRIMARY
MERCK INDEX
m1673
Created by admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
PRIMARY Merck Index
CHEBI
32499
Created by admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
PRIMARY
EVMPD
SUB05435MIG
Created by admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
PRIMARY
NCI_THESAURUS
C74142
Created by admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
PRIMARY
ECHA (EC/EINECS)
260-818-0
Created by admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
PRIMARY
PUBCHEM
34870
Created by admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
PRIMARY
FDA UNII
27T1I13L6G
Created by admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
PRIMARY
DRUG CENTRAL
161
Created by admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
PRIMARY
ChEMBL
CHEMBL418995
Created by admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
PRIMARY
CAS
57574-09-1
Created by admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
PRIMARY
DRUG BANK
DB04836
Created by admin on Fri Dec 15 16:23:46 GMT 2023 , Edited by admin on Fri Dec 15 16:23:46 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY